|Table of Contents|

Controversy and consensus on perioperative treatment of esophageal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
381-386
Research Field:
Publishing date:

Info

Title:
Controversy and consensus on perioperative treatment of esophageal cancer
Author(s):
HUANG Yuhong; ZHENG Tongsen
Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.
Keywords:
esophageal carcinoma; perioperative treatment; neoadjuvant therapy; adjuvant therapy
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2023.02.037
Abstract:
Esophageal cancer is the seventh malignant tumor in the world and the sixth leading cause of cancer-related death.Surgical treatment is the main treatment for resectable esophageal cancer,but for patients with locally advanced esophageal cancer,local recurrence and metastasis greatly shorten the survival time after surgical treatment alone,so except for very early tumors,all patients are recommended to receive neoadjuvant radiotherapy and chemotherapy or neoadjuvant chemotherapy before operation.However,there are still some patients who fail to receive neoadjuvant therapy before operation,so postoperative adjuvant therapy is needed to improve the prognosis of patients.This paper systematically reviews the research progress of perioperative treatment of esophageal cancer,including neoadjuvant therapy and adjuvant therapy,and summarizes the perioperative treatment of esophageal cancer combined with guidelines.

References:

［1］BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal of Clinical Oncology,2018,68(6):394-424.
［2］JUNG HK,TAE CH,LEE HA,et al.Treatment pattern and overall survival in esophageal cancer during a 13-year period:A NRTionwide cohort study of 6,354 Korean patients［J］.PLoS One,2020,15(4):e0231456.
［3］ALLUM WH,STENNING SP,BANCEWICZ J,et al.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer［J］.Journal of Clinical Oncology,2009,27(30):5062-5067.
［4］Medical research council oesophageal cancer working group;Surgical resection with or without preoperative chemotherapy in oesophageal cancer:a randomised controlled trial［J］.Lancet,2002,359(9319):1727-1733.
［5］ANDO N,KATO H,IGAKI H,et al.A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus(JCOG9907)［J］.Annals of Surgical Oncology,2012,19(1):68-74.
［6］中国临床肿瘤学会指南工作委员会.食管癌诊疗指南2021版［M］.北京：人民卫生出版社，2021:43-44. Guidelines working committee of the chinese society of clinical oncology,guidelines for the diagnosis and treatment of esophageal Cancer 2021 edition［M］.Beijing:People's Medical Publishing House，2021:43-44.
［7］TANAKA Y,YOSHIDA K,TANAHASHI T,et al.Phase II trial of neoadjuvant chemotherapy with docetaxel,nedaplatin,and S1 for advanced esophageal squamous cell carcinoma［J］.Cancer Science,2016,107(6):764-772.
［8］KOYANAGI K,KATO K,ITO Y,et al.Impact of preoperative therapy for locally advanced thoracic esophageal cancer on the risk of perioperative complications:Results from multicenter phase III trial JCOG 1109［J］.Journal of Clinical Oncology,2021,39(3):162-162.
［9］MOAVEN O,WANG TN,Combined modality therapy for management of esophageal cancer:current approach based on experiences from east and west［J］.Surgical Clinics of North America,2019,99(3):479-499.
［10］BURMEISTER B.Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase III trial［J］.Lancet Oncology,2005,6(9):659-668.
［11］MARIETTE C,DAHAN L,MORNEX F,et al.Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer:final analysis of randomized controlled phase III trial FFCD 9901［J］.Journal of Clinical Oncology,2014,32(23):2416-2422.
［12］VAN HAGEN P,HULSHOF MC,VAN LANSCHOT JJ,et al.Preoperative chemoradiotherapy for esophageal or junctional cancer［J］.The New England Journal of Medicine,2012,366(22):2074-2084.
［13］YANG H,LIU H,CHEN Y,et al.Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(NEOCRTEC5010):A phase III multicenter,randomized,open-label clinical trial［J］.Journal of Clinical Oncology,2018,36(27):2796-2803.
［14］中国临床肿瘤学会指南工作委员会.食管癌诊疗指南2021版［M］.北京：人民卫生出版社,2021:48-48. Guidelines working committee of the chinese society of clinical oncology,guidelines for the diagnosis and treatment of esophageal cancer 2021 edition［M］.Beijing:People's Medical Publishing House,2021:48-48.
［15］WANG X,GE X,WANG X,et al.S-1-Based chemoradiotherapy followed by consolidation chemotherapy with s-1 in elderly patients with esophageal squamous cell carcinoma:a multicenter phase II trial［J］.Frontiers in Oncology,2020,10:1499.
［16］WONGIYH,LAMKO,ZHANG RQ,et al.Neoadjuvant chemoradiotherapy using cisplatin and 5-FLuorouracil(PF)versus carboplatin and paclitaxel(CROSS Regimen)for esophageal squamous cell carcinoma(ESCC):A propensity score-matched study［J］.Annals of Surgery,2020,272(5):779-785.
［17］BRENNER B,PURIM O,GORDON N,et al.The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival:Mature results from a prospective phase Ib/II trial［J］.Radiotherapy and Oncology,2019,134(5):74-80.
［18］STROES CI,SCHOKKER S,CREEMERS A,et al.Phase II Feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma:trap study［J］.Journal of Clinical Oncology,2020,38(5):462-471.
［19］LIU J,LI Z,FU X,et al.127P A prospective phase Ⅱ clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer(TESCC)with multi-station lymph node metastases(NICE study):Preliminary results［J］.Annals of Oncology,2020,31:S1292-1292.
［20］GU Y,CHEN X,WANG D,et al.A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel,cisplatin,and S-1 for resectable esophageal squamous cell carcinoma(ESCC)［J］.Annals of Oncology,2020,31:S1307-S1308.
［21］YAMAMOTO S,KATO K,H DAIKO,et al.FRONTiER:A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma(JCOG1804E)-The short-term results of cohort A and B［J］.Journal of Clinical Oncology,2021,16(19):1351-1357.
［22］HONG MH,KIM HR,PARK SY,et al.A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma(ESCC)［J］.Journal of Clinical Oncology,2019,37(15):4027-4027.
［23］LI C,ZHAO S,ZHENG Y,et al.Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma(PALACE-1)［J］.European Journal of Cancer,2021,144(6):232-241.
［24］LI J,QIU R,HU Y,et al.Postoperative adjuvant therapy for patients with pN+esophageal squamous cell carcinoma［J］.Biomed Res Int,2021,2021(8571438):1-7.
［25］SEMENKOVICH TR,SUBRAMANIAN M,YAN Y,et al.Adjuvant therapy for node-positive esophageal cancer after induction and surgery:A multisite study［J］.Ann Thorac Surg,2019,108(3):828-836.
［26］ANDO N,IIZUKA T,IDE H,et al.Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan clinical oncology group study-JCOG9204［J］.Journal of Clinical Oncology,2003,21(24):4592-4596.
［27］LEE J,LEE KE,IM YH,et al.Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma［J］.Annals of Thoracic Surgery,2005,80(4):1170-1175.
［28］ZHAO P,YAN W,FU H,et al.Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma:A meta-analysis［J］.Thoracic Cancer,2018,9(8):1048-1055.
［29］中国临床肿瘤学会指南工作委员会.食管癌诊疗指南2021版［M］.北京：人民卫生出版社,2021:53-54. Guidelines working committee of the Chinese Society of Clinical Oncology,guidelines for the diagnosis and treatment of esophageal cancer 2021 edition［M］.Beijing:People's Medical Publishing House,2021:53-54.
［30］WONG AT,MENG S,RINEER J,et al.The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma［J］.Annals of Surgery,2017,265(6):1146-1151.
［31］YU J,OUYANG W,LI Y,et al.Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma:Analysis of surveillance,epidemiology,and end results database［J］.Cancer Medicine,2019,8(1):21-27.
［32］GAO H,SHANG X,GONG L,et al.Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma:A population based propensity matching analysis［J］.Thoracic Cancer,2020,11(2):243-252.
［33］SYA B,WZ C,WN A,et al.A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy［J］.Radiotherapy and Oncology,2019,140(6):159-166.
［34］YANG J,ZHANG W,XIAO Z,et al.The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T3N0M0 esophageal carcinoma:A propensity score-matched analysis［J］.Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer,2017,12(7):1143-1151.
［35］XIAO ZF,ZONG Y,LIANG J,et al.Value of radiotherapy after radical surgery for esophageal carcinoma:A report of 495 patients［J］.The Annals of Thoracic Surgery,2003,75(2):331-336.
［36］DENG W,YANG J,NI W,et al.Postoperative radiotherapy in pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma:interim report of a prospective,phase III,randomized controlled study［J］.Oncologist,2020,25(4):e701-e708.
［37］HSU PK,HUANG CS,WANG BY,et al.Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma［J］.Annals of Thoracic Surgery,2014,97(5):1734-1741.
［38］LYU J,CAO XF,ZHU B,et al.Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma［J］.World Journal of Gastroenterology,2010,16(13):1649-1654.
［39］WANG ZW,LUAN ZP,ZHANG W,et al.Postoperative chemoradiotherapy improves survival in esophageal squamous cell cancer with extracapsular lymph node extension［J］.Neoplasma,2014,61(6):732-738.
［40］CHEN H,WU Z,CHEN J,et al.Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma:a retrospective analysis of 426 cases［J］.Medical Oncology,2015,32(1):417-417.
［41］ZOU B,TU Y,LIAO D,et al.Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy:Which is more beneficial［J］.Thoracic Cancer,2020,11(3):631-639.
［42］MAMDANI H,SCHNEIDER BJ,ABUSHAHIN LI,et al.Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma:Results from big ten cancer research consortium study［J］.Journal of Clinical Oncology,2019,37(15):4058-4058.
［43］KELLY RJ，AJANI JA，KUZDZAL J,et al.Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer［J］.The New England Journal of Medicine,2021,384(13):1191-1203.

Memo

Memo:
黑龙江省自然科学基金杰出青年项目(编号：JQ2019H003)
Last Update: 1900-01-01